Persons with HIV infection are at increased risk of non-Hodgkin and Hodgkin lymphoma. Furthermore, HIV-infected patients had inferior outcomes and increased treatment-related morbidity and mortality over uninfected patients. In this exclusive interview with Rare Disease Report, Joseph Alvarnas MD, of the City of Hope Medical Center in Duarte CA discusses the recent study they performed showing the efficacy of using autologous hematopoietic stem cell transplantation in HIV positive patients with chemotherapy-sensitive, relapsed/refractory lymphoma.
Reference
Alvarnas J, Le Rademacher J, Wang Y, et al., Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) Trial. Presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco, CA. Abstract # 674.
[ Ссылка ]
